Cogent Biosciences, Inc. (COGT)
$34.59-$2.50 (-6.75%) Today
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 7 | 108,033 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
26 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 627 | $0.00 | - | |
| Peter Evan Harwin | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Christopher W. Cain | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
 Todd Shegog | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Arlene Morris | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Matthew Ros | Grant or award | Stock Option (Right to Buy) | 17,901 | $0.00 | - | |
| Andrew R. Robbins - Officer | Gift | Common Stock | 160,000 | $0.00 | - | |
| Andrew R. Robbins - Officer | Gift | Common Stock | 160,000 | $0.00 | - | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 686 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Other | Common Stock | 7,000,000 | - | - | |
| Fairmount Funds Management LLC - Director | Open-market sale | Common Stock | 7,000,000 | $34.66 | $242.62M | |
| Fairmount Funds Management LLC - Director | Other | Series A Convertible Preferred Stock | 28,000 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Open-market sale | Common Stock | 3,500,000 | $36.40 | $127.40M | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 643 | $0.00 | - | |
| Evan Kearns - Officer | Open-market sale | Common Stock | 65,000 | $38.70 | $2.52M | |
| John L. Green - Officer | Open-market sale | Common Stock | 77,000 | $38.68 | $2.98M | |
| Jessica Sachs - Officer | Open-market sale | Common Stock | 82,642 | $38.70 | $3.20M | |
| John Edward Robinson - Officer | Open-market sale | Common Stock | 90,000 | $38.74 | $3.49M | |
| John Edward Robinson - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| John Edward Robinson - Officer | Grant or award | Common Stock | 320,000 | $0.00 | - | |
| John Edward Robinson - Officer | Tax withholding / forfeiture | Common Stock | 139,998 | $39.45 | $5.52M | |
| John Edward Robinson - Officer | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Andrew R. Robbins - Officer | Grant or award | Common Stock | 185,000 | $0.00 | - | |
| Andrew R. Robbins - Officer | Grant or award | Common Stock | 840,000 | $0.00 | - | |
| Andrew R. Robbins - Officer | Tax withholding / forfeiture | Common Stock | 367,497 | $39.45 | $14.50M | |
| Andrew R. Robbins - Officer | Grant or award | Stock Option (Right to Buy) | 245,000 | $0.00 | - | |
| Cole Pinnow - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Cole Pinnow - Officer | Grant or award | Common Stock | 214,000 | $0.00 | - | |
| Cole Pinnow - Officer | Tax withholding / forfeiture | Common Stock | 94,800 | $39.45 | $3.74M | |
| Cole Pinnow - Officer | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Evan Kearns - Officer | Grant or award | Common Stock | 40,000 | $0.00 | - | |
| Evan Kearns - Officer | Grant or award | Common Stock | 260,000 | $0.00 | - | |
| Evan Kearns - Officer | Tax withholding / forfeiture | Common Stock | 125,602 | $39.45 | $4.95M | |
| Evan Kearns - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| Jessica Sachs - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Jessica Sachs - Officer | Grant or award | Common Stock | 320,000 | $0.00 | - | |
| Jessica Sachs - Officer | Tax withholding / forfeiture | Common Stock | 154,716 | $39.45 | $6.10M | |
| Jessica Sachs - Officer | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| John L. Green - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| John L. Green - Officer | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| John L. Green - Officer | Tax withholding / forfeiture | Common Stock | 145,007 | $39.45 | $5.72M | |
| John L. Green - Officer | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 1,642 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Open-market purchase | Common Stock | 2,777,777 | $9.00 | $25.00M | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 3,314 | $0.00 | - | |
| Karen Jean Ferrante | Grant or award | Stock Option (Right to Buy) | 2,034 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| ARLENE MORRIS | Director | 45,510 | $1.67M | View on EDGAR |
Cogent Biosciences, Inc. (COGT) had 7 insider filings in the last 90 days, with the most recent on 2026-07-06. The full record for COGT runs to 26 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of COGT were filed in the last 90 days. 1 purchase is on record for this company.
No insider sales of COGT were filed in the last 90 days. 6 sales are on record for this company.
This page tracks COGT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add COGT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
